Innovation: Health Technology and Systems

Featuring Dr. Natalia Trayanova, Murray B. Sachs Professor in Biomedical Engineering at Johns Hopkins University and a Professor of Medicine at the Johns Hopkins School of Medicine

Featuring Dr. Nestoras Mathioudakis, Johns Hopkins University, School of Medicine

Featuring Dr. Maia Hightower, Founder and CEP of Veritas Healthcare Insights

Featuring Dr. Serena Yeung-Levy, Stanford University

Waiving a $50 copay tripled patient uptake of AI eye screening. Patients still wanted a human to confirm the result.

More than 200 people filled the Johns Hopkins Carey Business School on March 5 and 6 for the annual Health Care Business Conference, with another 150 joining remotely. The two-day event, themed "Disruption to Discovery: Innovation in the Business of Health," tackled questions that cut across every corner of the industry: How should health systems adopt AI responsibly? What does value-based care actually look like in practice? And how do you move a good idea from a pilot program to something that works at scale?

Artificial intelligence (AI) and novel technologies offer tremendous potential for improving the health of older adults, but how key stakeholders make decisions about which technology to finance and adopt is not well understood.

Prediabetes can progress to type 2 diabetes (T2D), but individual risk varies widely.

Of the 1,247 artificial intelligence (AI) systems cleared by the U.S. Food and Drug Administration as of May 2025, many function as classifiers to help screen or diagnose specific medical conditions.

We propose straightforward principles to foster an evaluation-forward operating system that can transform the adoption of clinical artificial intelligence from a leap of faith into a stepwise, trust-building process.